<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567567</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL0532</org_study_id>
    <secondary_id>NCI-2009-01065</secondary_id>
    <secondary_id>CDR0000576571</secondary_id>
    <secondary_id>COG-ANBL0532</secondary_id>
    <secondary_id>ANBL0532</secondary_id>
    <secondary_id>ANBL0532</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00567567</nct_id>
  </id_info>
  <brief_title>Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma</brief_title>
  <official_title>Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial compares two different high-dose myeloablative chemotherapy
      regimens followed by autologous stem cell transplant as consolidation treatment of younger
      patients with high-risk neuroblastoma. All patients receive the same 6 cycles of initial
      multi-agent chemotherapy induction regimen. Peripheral blood stem cells are collected after
      the 2nd cycle of chemotherapy. Drugs used in chemotherapy work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
      combination chemotherapy before surgery may make the tumor smaller and reduce the amount of
      normal tissue that needs to be removed. Patients underwent resection of their primary tumor
      mass after 5 cycles of chemotherapy. Those patients without progressive disease at completion
      of induction therapy who has sufficient stem cells collected and had adequate organ function
      were eligible to proceed to consolidation therapy. Those patients who met consolidation
      eligibility were randomized to either a single myeloablative regimen or 2 myeloablative
      regimens delivered in tandem followed by re-infusion of autologous stem cells. Patients
      received radiation therapy after recovery from the assigned myeloablative therapy. It is not
      yet known which regimen of high-dose chemotherapy is more effective for patients with
      high-risk neuroblastoma undergoing a peripheral blood stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To improve the 3-year event-free survival (EFS) rate of high-risk neuroblastoma patients
      through treatment with a tandem consolidation of thiotepa/cyclophosphamide followed by
      carboplatin/etoposide/melphalan (CEM) as compared to single CEM consolidation.

      II. To improve the rate of end-induction complete response and very good partial response,
      compared to historical controls, by use of a topotecan-containing induction regimen.

      III. To improve the 3-year local control rate, compared to historical controls, by increasing
      the local dose of radiation to the residual primary tumor for patients with less than a gross
      total resection.

      SECONDARY OBJECTIVES:

      I. To evaluate the pharmacogenetic relationship of cyclophosphamide metabolizing enzymes
      (i.e., cytochrome p 450 2B6 [CYP2B6], CYP2C9, and glutathione S-transferase alpha 1 [GSTA1]
      genotypes) with toxicity and response following dose-intensive cyclophosphamide and topotecan
      induction chemotherapy.

      II. To determine if resection completeness is predictive of local control rate or EFS rate in
      patients with high-risk neuroblastoma.

      III. To prospectively describe the complications related to efforts at local control (i.e.,
      surgery and radiotherapy) in patients with high-risk neuroblastoma.

      IV. To describe the neurologic outcome of patients with paraspinal primary neuroblastoma
      tumors.

      V. To determine the variability of isotretinoin pharmacokinetics (PKs) and relationship to
      pharmacogenomic parameters.

      VI. To determine if isotretinoin PK levels are predictive of the EFS rate or associated with
      systemic toxicity following isotretinoin.

      VII. To determine if pharmacogenomic variations are predictive of the EFS rate or associated
      with systemic toxicity following isotretinoin.

      VIII. To evaluate total topotecan PKs and correlate with patient specific data for use in an
      ongoing topotecan population PK analysis.

      IX. To evaluate the presence and function of T cells capable of recognizing neuroblastoma by
      assessing the following; if T cells recognizing the neuroblastoma antigen, survivin,
      circulate at diagnosis; if these T cells can be expanded using autologous antigen presenting
      cells (APCs); if these T cells will kill neuroblastoma cells as detected in functional
      assays; and if the presence and activity of anti-neuroblastoma immunity is decreased by stem
      cell transplantation.

      X. To characterize the recovery of T-cell numbers after myeloablative consolidation and
      hematopoietic stem cell transplantation (HSCT) and to assess the impact of tandem
      myeloablative consolidation on T-cell recovery.

      XI. To characterize minimal residual disease burden using reverse transcriptase-polymerase
      chain reaction (RT-PCR) evaluation of a panel of neuroblastoma specific transcripts in
      patient bone marrow and peripheral blood following induction chemotherapy and after single
      versus tandem myeloablative chemotherapy and to evaluate impact on EFS.

      XII. To evaluate the EFS and overall survival of patients nonrandomly assigned to treatment
      with single myeloablative transplant (Arm A).

      OUTLINE:

      INDUCTION CHEMOTHERAPY:

      COURSES 1 AND 2: Patients receive cyclophosphamide IV over 30 minutes and topotecan
      hydrochloride IV over 30 minutes on days 1-5 and filgrastim (G-CSF) subcutaneously (SC) or IV
      beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days
      for 2 courses. Patients undergo peripheral blood stem cell (PBSC) mobilization and harvest
      after course 2.

      COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4, etoposide IV over 1
      hour on days 1-3, and G-CSF SC or IV beginning on day 5 and continuing until blood counts
      recover. Treatment repeats every 21 days for 2 courses. Patients undergo surgical resection
      of soft tissue disease after course 5 (or after course 6 if medically necessary).

      COURSES 4 AND 6: Patients receive cyclophosphamide IV over 6 hours on days 1-2, doxorubicin
      hydrochloride IV over 24 hours on days 1-3, vincristine IV on days 1-3, and G-CSF SC or IV
      beginning on day 5 and continuing until blood counts recover. Treatment repeats every 21 days
      for 2 courses.

      At end induction, those patients with adequate organ function and peripheral blood stem cell
      collection are eligible to undergo randomized assignment to Consolidation therapy.
      Randomization is stratified by initial stage of disease, MYCN status, and response to
      induction chemotherapy (complete response/very good partial response vs partial response vs
      mixed response/no response). Patients are randomized to 1 of 2 arms (single myeloablative
      regimen with autologous stem cell support, arm A or tandem (2) myeloablative regimens each
      followed by autologous stem cell support, arm B). Patients 12-18 months old (i.e., 365-547
      days) with stage IV, MYCN nonamplified tumor with unfavorable histopathology or diploid DNA
      content or with indeterminant histology or ploidy AND patients who are greater than 547 days
      of age with stage III, MYCN nonamplified tumor AND unfavorable histopathology or
      indeterminant histology will be nonrandomly assigned to Arm A.

      Consolidation chemotherapy was recommended to begin no later than 8 weeks after the start of
      induction course 6.

      CONSOLIDATION THERAPY:

      ARM A (single myeloablative consolidation): Patients receive melphalan IV over 15-30 minutes
      on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to
      -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients
      undergo autologous peripheral blood stem cell transplant (PBSCT) on day 0.

      ARM B (tandem myeloablative consolidation): Patients receive thiotepa IV over 2 hours on days
      -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on
      day 0 and continuing until blood counts recover. Following clinical recovery from initial
      myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm
      A but at reduced dosages. Patients undergo autologous PBSCT on day 0.

      RADIOTHERAPY: Patients undergo external beam radiation therapy (EBRT) to primary site of
      disease as well as to MIBG-avid sites seen at pre-transplantation (i.e., end- induction)
      evaluation no sooner than day 28 and recommended by 42 days post-transplant. An additional
      boost of radiotherapy is administered to residual tumor at primary site.

      MAINTENANCE THERAPY: Patients are encouraged to enroll onto Children's Oncology Group
      (COG)-ANBL0032 following assessment of tumor response after completion of the consolidation
      phase and radiotherapy. Beginning on day 60 post-transplantation patients receive oral
      isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for up to 6 months in
      the absence of disease progression or unacceptable toxicity.

      Patients undergo blood and tissue sample collection periodically for the following analyses;
      correlation between peak serum concentration level of cyclophosphamide metabolites and the
      existence of polymorphisms in genes involved in cyclophosphamide metabolism, event-free
      survival, and toxicity rates; pharmacogenomics for uridine diphosphate (UDP)
      glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1), UGT2B7, CYP2C8 and CYP3A7 alleles;
      topotecan systemic clearance; survivin-specific cytotoxic T-lymphocytes (CTLs) detected using
      peptide/major histocompatibility complex (MHC) tetramers in human leukocyte antigen (HLA)-A2+
      patients; interferon (IFN)-gamma production in enzyme-linked immunospot (ELISPOT) assays to
      APCs loaded with tumor ribonucleic acid (RNA), survivin RNA, or control RNA; response of
      APC-stimulated CTL response to neuroblastoma cells; rate of T cell recovery; and proportion
      of patients with neuroblastoma detected in bone marrow and peripheral blood using RT-PCR and
      immunohistochemistry (IHC).

      After completion of study treatment, patients are followed up periodically for 5 years and
      then annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival Rate</measure>
    <time_frame>Three years, from time of randomization</time_frame>
    <description>Comparison of EFS curves, starting from the time of randomization, by treatment group (single CEM vs. tandem CEM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of Local Recurrence</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence rate of local recurrence comparison between ANBL0532 patients randomized or assigned to receive single CEM transplant and boost radiation versus the historical A3973 patients who were transplanted and received boost radiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response After Induction Therapy</measure>
    <time_frame>Study enrollment to the end of induction therapy</time_frame>
    <description>Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)-&gt;90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; &gt;50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by &gt;50%. Mixed Response (MR)-&gt;50% reduction of any measurable lesion (primary or metastases) with &lt;50% reduction in other sites; no new lesions; &lt;25% increase in any existing lesion. No Response (NR)-no new lesions; &lt;50% reduction but &lt;25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by &gt;25%; previous negative marrow positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Greater Than or Equal to Grade 3 Neutropenia</measure>
    <time_frame>21 days</time_frame>
    <description>A logistic regression model will be used to test the ability of the number of days of neutropenia to predict the presence of a polymorphism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Greater Than or Equal to Grade 3 Thrombocytopenia</measure>
    <time_frame>21 days</time_frame>
    <description>A logistic regression model will be used to test the ability of the number of days of thrombocytopenia to predict the presence of a polymorphism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content &amp; Pts&gt;547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Kaplan-Meier curves of EFS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells</measure>
    <time_frame>Up to 6 months after completion of assigned myeloablation therapy</time_frame>
    <description>A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic Symptom Resolution in Patients With Primary Tumors With Intraspinal Extension</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Descriptive tabulation of the proportion of patients with resolution of neurologic symptoms by type of symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients &gt; 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies</measure>
    <time_frame>Day 1 of each course</time_frame>
    <description>Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic Variants in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine if pharmacogenomic variations are predictive of EFS, a logrank test comparison of patients with vs without a given polymorphism will be made. A Fisher's exact test will test for association of the presence of a polymorphism with the occurrence of systemic toxicity (CTC grade 3 or 4 skin, hypercalcemia, or hepatic toxicity). These tests will be performed for UGT1A1, UGT2B7, CYP2C8 and CYP3A7 alleles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and Function of T Cells Capable of Recognizing Neuroblastoma</measure>
    <time_frame>Up to 6 months (end of therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Neuroblastoma Detected in Bone Marrow and Peripheral Blood Using RT-PCR Technique</measure>
    <time_frame>Baseline</time_frame>
    <description>Will be calculated overall and by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>42 days</time_frame>
    <description>A chi-square test of association will be used to compare the proportion of responders with versus without a polymorphism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>A chi-square test of proportions will be used to test for association between the proportion of patients who achieve a surgical CR and the proportion of patients who do not relapse in the primary. A logrank test will compare the EFS curves for degree of surgical response (CR vs. &lt; CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topotecan Systemic Clearance</measure>
    <time_frame>Day 1 of courses 1-2</time_frame>
    <description>Median topotecan systemic clearance for courses 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Radiotherapy Complication</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients by type of surgical complication and type of radiation therapy complication will be descriptively tabulated. The complications are: bowel obstruction, chylous leak, renal injury/atrophy/loss and diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Surgical Complication</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients by type of surgical complication and type of radiation therapy complication will be descriptively tabulated. The complications are: bowel obstruction, chylous leak, renal injury/atrophy/loss and diarrhea.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">665</enrollment>
  <condition>Localized Resectable Neuroblastoma</condition>
  <condition>Localized Unresectable Neuroblastoma</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Regional Neuroblastoma</condition>
  <condition>Stage 4 Neuroblastoma</condition>
  <condition>Stage 4S Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not Assigned</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients either failed during Induction therapy or refused randomization, and hence did not receive any of the Consolidation therapy (i.e., Consolidation Arm A: single HST (CEM) myeloablative consolidation or Consolidation Arm B: tandem HST (CEM) myeloablative consolidation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell transplant</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo EBRT</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>13-cis retinoic acid</other_name>
    <other_name>13-cis-Retinoate</other_name>
    <other_name>13-cis-Retinoic Acid</other_name>
    <other_name>13-cis-Vitamin A Acid</other_name>
    <other_name>13-cRA</other_name>
    <other_name>Accure</other_name>
    <other_name>Accutane</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>cis-Retinoic Acid</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Isotretinoinum</other_name>
    <other_name>Isotrex</other_name>
    <other_name>Isotrexin</other_name>
    <other_name>Neovitamin A</other_name>
    <other_name>Neovitamin A Acid</other_name>
    <other_name>Oratane</other_name>
    <other_name>Retinoicacid-13-cis</other_name>
    <other_name>Ro 4-3780</other_name>
    <other_name>Ro-4-3780</other_name>
    <other_name>Roaccutan</other_name>
    <other_name>Roaccutane</other_name>
    <other_name>Roacutan</other_name>
    <other_name>Sotret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell transplant</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <other_name>1,1',1''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Liposome</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Consolidation Arm A: single myeloablative consolidation</arm_group_label>
    <arm_group_label>Consolidation Arm B: tandem myeloablative consolidation</arm_group_label>
    <arm_group_label>Not Assigned</arm_group_label>
    <other_name>Marqibo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of neuroblastoma or ganglioneuroblastoma by histology or as evidenced by the
             presence of clumps of tumor cells in bone marrow and elevated catecholamine
             metabolites in urine meeting any of the following criteria:

               -  Patients with newly diagnosed neuroblastoma with International Neuroblastoma
                  Staging System (INSS) stage 4 disease are eligible with the following:

                    -  MYCN amplification (i.e., greater than four-fold increase in MYCN signals as
                       compared to reference signals), regardless of age or additional biologic
                       features

                    -  Age &gt; 18 months (i.e., &gt; 547 days) regardless of biologic features

                    -  Age 12-18 months (i.e., 365-547 days) with none of the following three
                       favorable biologic features (i.e., non-amplified MYCN, favorable pathology,
                       and deoxyribonucleic acid [DNA] index &gt; 1)

               -  Patients with newly diagnosed neuroblastoma with INSS stage 3 are eligible with
                  the following:

                    -  MYCN amplification (i.e., greater than four-fold increase in MYCN signals as
                       compared to reference signals), regardless of age or additional biologic
                       features

                    -  Age &gt; 18 months (i.e., &gt; 547 days) with unfavorable pathology, regardless of
                       MYCN status

               -  Patients with newly diagnosed INSS stage 2a or 2b with MYCN amplification (i.e.,
                  greater than four-fold increase in MYCN signals as compared to reference
                  signals), regardless of age or additional biologic features

               -  Patients with newly diagnosed INSS stage 4s with MYCN amplification (i.e.,
                  greater than four-fold increase in MYCN signals as compared to reference
                  signals), regardless of additional biologic features

               -  Patients &gt;= 365 days initially diagnosed with INSS stage 1, 2, or 4S and who
                  progressed to a stage 4 without interval chemotherapy

                    -  Must have been enrolled on COG-ANBL00B1

          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70mL/min OR serum
             creatinine based on age/gender as follows:

               -  1 month to &lt; 6 months: 0.4 mg/dL

               -  6 months to &lt; 1 year: 0.5 mg/dL

               -  1 to &lt; 2 years: 0.6 mg/dL

               -  2 to &lt; 6 years: 0.8 mg/dL

               -  6 to &lt; 10 years: 1 mg/dL

               -  10 to &lt; 13 years: 1.2 mg/dL

               -  10 to &lt; 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)

               -  &gt;= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 10 times ULN for
             age

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Shortening fraction &gt;= 27% by echocardiogram (ECHO) OR left ventricular ejection
             fraction (LVEF) &gt;= 50% by radionuclide angiogram

          -  No known contraindication (e.g., size, weight or physical condition) to peripheral
             blood stem cell collection

          -  No prior systemic therapy except for localized emergency radiation to sites of
             life-threatening or function-threatening disease

          -  No more than one course of chemotherapy per low- or intermediate-risk neuroblastoma
             therapy prior to determination of MYCN amplification and histology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System - Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Services</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalamazoo Center for Medical Studies</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital-Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center-Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Cancer Treatment Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T C Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Children's Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital-Brisbane</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chedoke-McMaster Hospitals</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1145</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group - Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <results_first_submitted>January 20, 2017</results_first_submitted>
  <results_first_submitted_qc>May 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single HST (CEM)</title>
          <description>Induction therapy + single myeloablative consolidation</description>
        </group>
        <group group_id="P2">
          <title>Tandem HST (CEM), Randomly Assigned</title>
          <description>Induction therapy + tandem myeloablative consolidation</description>
        </group>
        <group group_id="P3">
          <title>Not Assigned</title>
          <description>Patients that either failed during Induction therapy or refused randomization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="278"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal by patient/parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled another COG therapeutic study</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable adequate stem cell for transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single HST (CEM)</title>
          <description>Induction therapy + single myeloablative consolidation</description>
        </group>
        <group group_id="B2">
          <title>Tandem HST (CEM), Randomly Assigned</title>
          <description>Induction therapy + tandem myeloablative consolidation</description>
        </group>
        <group group_id="B3">
          <title>Not Assigned</title>
          <description>Patients that either failed during Induction therapy or refused randomization</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="279"/>
            <count group_id="B4" value="665"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="277"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="2.9"/>
                    <measurement group_id="B2" value="2.9" spread="2.4"/>
                    <measurement group_id="B3" value="3.4" spread="2.8"/>
                    <measurement group_id="B4" value="3.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="559"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="243"/>
                    <measurement group_id="B4" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival Rate</title>
        <description>Comparison of EFS curves, starting from the time of randomization, by treatment group (single CEM vs. tandem CEM)</description>
        <time_frame>Three years, from time of randomization</time_frame>
        <population>All eligible, randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival Rate</title>
          <description>Comparison of EFS curves, starting from the time of randomization, by treatment group (single CEM vs. tandem CEM)</description>
          <population>All eligible, randomized patients.</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="41.1" upper_limit="56.5"/>
                    <measurement group_id="O2" value="61.8" lower_limit="53.8" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The event-free survival distributions of patients randomized to Regimen A - Single HST (CEM) and randomized to Regimen B - Tandem HST (CEM) were compared using the log-rank test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <method>Log Rank</method>
            <param_type>Log Rank Test Statistic</param_type>
            <param_value>6.9883</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Local Recurrence</title>
        <description>Cumulative incidence rate of local recurrence comparison between ANBL0532 patients randomized or assigned to receive single CEM transplant and boost radiation versus the historical A3973 patients who were transplanted and received boost radiation.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Eligible patients randomized or assigned to the single HST (CEM) treatment arm who also received boost radiation.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Local Recurrence</title>
          <description>Cumulative incidence rate of local recurrence comparison between ANBL0532 patients randomized or assigned to receive single CEM transplant and boost radiation versus the historical A3973 patients who were transplanted and received boost radiation.</description>
          <population>Eligible patients randomized or assigned to the single HST (CEM) treatment arm who also received boost radiation.</population>
          <units>Percentage 3-year cumulative incidence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="7.5" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The cumulative incidence rates of local recurrence between patients from ANBL0532 randomized or assigned to receive single CEM transplant and boost radiation and A3973 patients who were transplanted and received boost radiation were compared using Gray's test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5615</p_value>
            <method>Gray's test for competing risks</method>
            <param_type>Gray's test statistic</param_type>
            <param_value>0.33709</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response After Induction Therapy</title>
        <description>Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)-&gt;90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; &gt;50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by &gt;50%. Mixed Response (MR)-&gt;50% reduction of any measurable lesion (primary or metastases) with &lt;50% reduction in other sites; no new lesions; &lt;25% increase in any existing lesion. No Response (NR)-no new lesions; &lt;50% reduction but &lt;25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by &gt;25%; previous negative marrow positive.</description>
        <time_frame>Study enrollment to the end of induction therapy</time_frame>
        <population>Eligible patients evaluated for response at the end of induction therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
          <group group_id="O3">
            <title>Not Assigned</title>
            <description>Patients that either failed during Induction therapy or refused randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Response After Induction Therapy</title>
          <description>Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)-&gt;90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; &gt;50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by &gt;50%. Mixed Response (MR)-&gt;50% reduction of any measurable lesion (primary or metastases) with &lt;50% reduction in other sites; no new lesions; &lt;25% increase in any existing lesion. No Response (NR)-no new lesions; &lt;50% reduction but &lt;25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by &gt;25%; previous negative marrow positive.</description>
          <population>Eligible patients evaluated for response at the end of induction therapy.</population>
          <units>Proportion participants that responded</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.47" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.41" upper_limit="0.56"/>
                    <measurement group_id="O3" value="0.35" lower_limit="0.29" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Chi-square test of proportions in all patients to compare the proportion of responders (complete response [CR]+ very good partial response [VGPR]) at the end of induction therapy in this study to an analogous cohort of responders in A3973.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Chi-squared</method>
            <param_type>Chi-squared test statistic</param_type>
            <param_value>8.5751</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Greater Than or Equal to Grade 3 Neutropenia</title>
        <description>A logistic regression model will be used to test the ability of the number of days of neutropenia to predict the presence of a polymorphism.</description>
        <time_frame>21 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Greater Than or Equal to Grade 3 Thrombocytopenia</title>
        <description>A logistic regression model will be used to test the ability of the number of days of thrombocytopenia to predict the presence of a polymorphism.</description>
        <time_frame>21 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content &amp; Pts&gt;547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).</title>
        <description>Kaplan-Meier curves of EFS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All eligible patients non-randomly assigned to single CEM</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content &amp; Pts&gt;547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).</title>
          <description>Kaplan-Meier curves of EFS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
          <population>All eligible patients non-randomly assigned to single CEM</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="55.1" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells</title>
        <description>A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed.</description>
        <time_frame>Up to 6 months after completion of assigned myeloablation therapy</time_frame>
        <population>All eligible patients that had CD3, CD4 and CD8T-cell count evaluated at the end of reporting period 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells</title>
          <description>A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed.</description>
          <population>All eligible patients that had CD3, CD4 and CD8T-cell count evaluated at the end of reporting period 3.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200" lower_limit="23" upper_limit="1549"/>
                    <measurement group_id="O2" value="255.5" lower_limit="13" upper_limit="2987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="8" upper_limit="626"/>
                    <measurement group_id="O2" value="81" lower_limit="4" upper_limit="1186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="8" upper_limit="1170"/>
                    <measurement group_id="O2" value="151" lower_limit="4" upper_limit="2529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurologic Symptom Resolution in Patients With Primary Tumors With Intraspinal Extension</title>
        <description>Descriptive tabulation of the proportion of patients with resolution of neurologic symptoms by type of symptom.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients &gt; 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology</title>
        <description>Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients &gt; 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology</title>
          <description>Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.</description>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="65.1" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies</title>
        <description>Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532</description>
        <time_frame>Day 1 of each course</time_frame>
        <population>Eligible patients evaluated for peak serum concentration level of isotretinoin.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
          <group group_id="O3">
            <title>Not Assigned</title>
            <description>Patients that either failed during Induction therapy or refused randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies</title>
          <description>Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532</description>
          <population>Eligible patients evaluated for peak serum concentration level of isotretinoin.</population>
          <units>Micromolar</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0" upper_limit="9.22"/>
                    <measurement group_id="O2" value="1.36" lower_limit="0" upper_limit="12.93"/>
                    <measurement group_id="O3" value="1.26" lower_limit="0" upper_limit="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The relationship between the peak serum isotretinoin concentration level with event-free survival was explored with a Cox proportional hazards model. Eligible patients treated with isotretinoin on A3973, ANBL0032, ANBL0532, or ANBL0931 with peak serum concentration level data were included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6853</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacogenetic Variants in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies</title>
        <description>To determine if pharmacogenomic variations are predictive of EFS, a logrank test comparison of patients with vs without a given polymorphism will be made. A Fisher’s exact test will test for association of the presence of a polymorphism with the occurrence of systemic toxicity (CTC grade 3 or 4 skin, hypercalcemia, or hepatic toxicity). These tests will be performed for UGT1A1, UGT2B7, CYP2C8 and CYP3A7 alleles.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence and Function of T Cells Capable of Recognizing Neuroblastoma</title>
        <time_frame>Up to 6 months (end of therapy)</time_frame>
        <population>The data was not collected to assess this study aim.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
          <group group_id="O3">
            <title>Not Assigned</title>
            <description>Patients that either failed during Induction therapy or refused randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Presence and Function of T Cells Capable of Recognizing Neuroblastoma</title>
          <population>The data was not collected to assess this study aim.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Neuroblastoma Detected in Bone Marrow and Peripheral Blood Using RT-PCR Technique</title>
        <description>Will be calculated overall and by treatment arm.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>A chi-square test of association will be used to compare the proportion of responders with versus without a polymorphism.</description>
        <time_frame>42 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Response</title>
        <description>A chi-square test of proportions will be used to test for association between the proportion of patients who achieve a surgical CR and the proportion of patients who do not relapse in the primary. A logrank test will compare the EFS curves for degree of surgical response (CR vs. &lt; CR).</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Topotecan Systemic Clearance</title>
        <description>Median topotecan systemic clearance for courses 1 and 2.</description>
        <time_frame>Day 1 of courses 1-2</time_frame>
        <population>Eligible patients evaluated for topotecan systemic clearance.</population>
        <group_list>
          <group group_id="O1">
            <title>Single HST (CEM)</title>
            <description>Induction therapy + single myeloablative consolidation</description>
          </group>
          <group group_id="O2">
            <title>Tandem HST (CEM), Randomly Assigned</title>
            <description>Induction therapy + tandem myeloablative consolidation</description>
          </group>
          <group group_id="O3">
            <title>Not Assigned</title>
            <description>Patients that either failed during Induction therapy or refused randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Topotecan Systemic Clearance</title>
          <description>Median topotecan systemic clearance for courses 1 and 2.</description>
          <population>Eligible patients evaluated for topotecan systemic clearance.</population>
          <units>L/h/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="14.9" upper_limit="49.4"/>
                    <measurement group_id="O2" value="28.1" lower_limit="11.6" upper_limit="42.7"/>
                    <measurement group_id="O3" value="28.5" lower_limit="16.3" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Radiotherapy Complication</title>
        <description>The proportion of patients by type of surgical complication and type of radiation therapy complication will be descriptively tabulated. The complications are: bowel obstruction, chylous leak, renal injury/atrophy/loss and diarrhea.</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Surgical Complication</title>
        <description>The proportion of patients by type of surgical complication and type of radiation therapy complication will be descriptively tabulated. The complications are: bowel obstruction, chylous leak, renal injury/atrophy/loss and diarrhea.</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>We've excluded the ineligibles from this table.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single HST (CEM)</title>
          <description>Induction therapy + single myeloablative consolidation</description>
        </group>
        <group group_id="E2">
          <title>Tandem HST (CEM), Randomly Assigned</title>
          <description>Induction therapy + tandem myeloablative consolidation</description>
        </group>
        <group group_id="E3">
          <title>Not Assigned</title>
          <description>Patients that either failed during Induction therapy or refused randomization</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>17200-Blood and lymphatic system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>25800-Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>33300-Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>39600-Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>39700-Hemolytic uremic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20000-Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>51700-Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>63100-Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>72700-Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>31900-Eye disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>14900-Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>35900-Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>36700-Gastrointestinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>36900-Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>53000-Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>70100-Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>75700-Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>81900-Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>82200-Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>24600-Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>55700-Multi-organ failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>40000-Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>40600-Hepatobiliary disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66500-Portal hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66600-Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>13800-Aortic injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>45400-Injury to inferior vena cava</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>47700-Intraoperative renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>24100-Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>45800-INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>88200-Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>54900-Metabolism and nutrition disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>81700-Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>58000-Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>81200-Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>25300-Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>29000-Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>56600-Myelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>58100-Nervous system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>71000-Renal and urinary disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>19200-Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>27800-Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>29700-Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>65900-Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66300-Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>69000-Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>71500-Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>75300-Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>79000-Surgical and medical procedures - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="230" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="176"/>
                <counts group_id="E3" events="42" subjects_affected="33" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>17200-Blood and lymphatic system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>25800-Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>33300-Febrile neutropenia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="32" subjects_at_risk="206"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="176"/>
                <counts group_id="E3" events="53" subjects_affected="46" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20000-Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>20100-Cardiac disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>39000-Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>63100-Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>72700-Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>27900-Ear and labyrinth disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>38900-Hearing impaired</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>11200-Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>31900-Eye disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10100-Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>14900-Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>22100-Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>25700-Diarrhea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="206"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>26600-Duodenal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>29400-Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>31200-Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>36400-Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>36700-Gastrointestinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>44200-Ileal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>44600-Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>46300-Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>53000-Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="206"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="176"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>57600-Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>58900-Obstruction gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>59700-Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>75600-Small intestinal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>75700-Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>81900-Typhlitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>87900-Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>28200-Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>33200-Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>33900-Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>48700-Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>35500-Gallbladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>40600-Hepatobiliary disorders - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66500-Portal hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>12000-Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>13100-Anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>44700-Immune system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>13400-Anorectal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>16800-Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>25600-Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>29500-Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>38300-Gum infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="48" subjects_affected="36" subjects_at_risk="206"/>
                <counts group_id="E2" events="45" subjects_affected="32" subjects_at_risk="176"/>
                <counts group_id="E3" events="68" subjects_affected="39" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>60100-Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>62500-Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66100-Pleural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>75200-Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>76000-Small intestine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>82300-Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>83100-Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>88900-Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>14500-Arterial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>34900-Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>46500-Intraoperative arterial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66800-Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66900-Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>80700-Tracheal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>86400-Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="206"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>11800-Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="206"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>24100-Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>34000-Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>45800-INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>52600-Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>53700-Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="254" subjects_affected="185" subjects_at_risk="206"/>
                <counts group_id="E2" events="192" subjects_affected="148" subjects_at_risk="176"/>
                <counts group_id="E3" events="287" subjects_affected="217" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="237" subjects_affected="146" subjects_at_risk="206"/>
                <counts group_id="E2" events="177" subjects_affected="124" subjects_at_risk="176"/>
                <counts group_id="E3" events="269" subjects_affected="175" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>73900-Serum amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>83600-Urine output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="32" subjects_at_risk="206"/>
                <counts group_id="E2" events="42" subjects_affected="30" subjects_at_risk="176"/>
                <counts group_id="E3" events="52" subjects_affected="36" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>11900-Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>24700-Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>41400-Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>41700-Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42500-Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>42900-Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="38" subjects_at_risk="206"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="176"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43200-Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>48500-Iron overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>14700-Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>16200-Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>37300-Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>55900-Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>60700-Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>58000-Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>15300-Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>22000-Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>25300-Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>31800-Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>38800-Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>58100-Nervous system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>63900-Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>64100-Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>73600-Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>11400-Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>23000-Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>39300-Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>62600-Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>11300-Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>14100-Apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>15100-Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>15400-Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>19200-Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>27800-Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>29700-Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>64900-Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>65300-Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>65900-Pleural effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>66300-Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>68700-Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>69000-Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>71500-Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>78100-Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>68400-Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>69700-Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>75300-Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>84100-Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>53300-Lymph leakage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>79600-Thromboembolic event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>86500-Vascular disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>87500-Visceral arterial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>Resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

